ESSA PharmaEPIX
About: ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
Employees: 35
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
225% more call options, than puts
Call options by funds: $179K | Put options by funds: $55K
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
44% more funds holding
Funds holding: 32 [Q3] → 46 (+14) [Q4]
5.09% less ownership
Funds ownership: 79.11% [Q3] → 74.03% (-5.09%) [Q4]
72% less capital invested
Capital invested by funds: $213M [Q3] → $58.8M (-$154M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for EPIX.
Financial journalist opinion
Based on 59 articles about EPIX published over the past 30 days









